Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
FARMINGTON HILLS, Mich., Feb. 05, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that clinical data from its ZETA-1 trial on a person-level scale evaluating APX3330 in diabetic retinopathy (DR) were presented at the 21st Annual Angiogenesis, Exudation, and Degeneration 2024 Conference, which took place virtually on Saturday, February 3, 2024. The presentation, titled APX3330 Oral Treatment to Slow the Progression of Diabetic Retinopathy Using a Binocular DRSS Severity Scale as a Registrational Endpoint, was delivered by Veeral Sheth, M.D., M.B.A., a practicing retina specialist at University Retina, and Clinical Assistant Professor at the University of Illinois.
Related news for (OCUP)
- ocuphire pharma announces acquisition of opus genetics
- ocuphire pharma announces publication of full phase 3 results of phentolamine ophthalmic solution 0.75% for pharmacologically-induced mydriasis in ophthalmology
- update – ocuphire pharma initiates vega-3 phase 3 trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia
- ocuphire pharma initiates vega-3 phase 3 trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia